Abstract:Abstract Funding Acknowledgements Type of funding sources: None. Background Pulmonary vein isolation (PVI) is an established therapy for symptomatic atrial fibrillation (AF) and the cryoballoon (CB) has become a standard tool for PVI. But the technology is limited in certain ways. The novel multi-electrode balloon catheter promises the advantages of a balloon technology in combination with 3D-mapping and more flexible energy delivery. Purpose There is very limited data available regarding the safety and efficacy of the Heliostar™ RF-balloon. We therefore aimed to assess procedure characteristics, efficacy, and safety in direct comparison with the established CB. Methods All patients undergoing PVI using the Heliostar™ between September 2021 and March 2022 were included in this single center registry. Procedural data and outcome were assessed and compared with data from consecutive patients undergoing initial PVI for paroxysmal AF with the CB from our specifically designed database. Results A total of 251 consecutive patients (63±13 years, 54% male) were included. Of those 28 patients undergoing RF-balloon and 223 patients CB PVI. Baseline parameters did not differ between groups. Acute PVI was achieved in all patients using CB and in 26/28 patients (93%) with the RF-balloon. In 2/28 patients an additional single tip catheter was needed. A mean of 11.2±4.9 RF-applications with 2.8±1.4 applications per vein (LSPV 3.2±2.9, LIPV 2.6±2.5, RSPV 2.8±2.0 and RIPV 1.8±0.8) were necessary to achieve a durable isolation. Using the CB, significantly less applications (5.9±2.2;p=<0.001) were needed. While procedure duration (111±30min. vs. 70min.;p=<0.001) and fluoroscopy time (17.2±6.3min. vs. 11.5±4.8min.;p=<0.001) were longer in the Heliostar™ group, time to isolation was significantly shorter using the RF-balloon: LSPV 23.5±12.3 sec. vs. 54.6±38.3 sec. (p=<0.001); LIPV 18.6±10.4 sec. vs. 61.2±46.5 sec. (p=0.002); RSPV 17.4±10.9 sec. vs. 62.5±53.9 sec. (p=<0.001); RIPV 16.1±9.3 sec. vs. 59.3±35.9 sec. (p=<0.001). One pericardial effusion occurred in the Heliostar™ group due to complicated transseptal access. During CB PVI in 4/223 patients (1.8%) a phrenic nerve palsy was observed, which resolved in all patients within 12-month. After 12-month 80% of patients in the Heliostar™ and 79% of patients in the CB group (p=0.9) were free from atrial arrhythmias. Conclusion The novel multi-electrode RF-balloon has shown to be safe and effective with good long-term results. In comparison with the CB, time to isolation was significantly shorter but procedure durations were longer and fluoroscopy exposition was higher using the first generation Heliostar™ without LassostarNav®. This can be attributed to the learning curve applying a new ablation system and the necessity for separate 3D map preparation. More experience is needed in the future, especially with the new generation Heliostar™ to determine the real benefits.

In vivo safety and pulmonary vein isolation performance of a new cryoballoon for the treatment of atrial fibrillation

One‐year outcomes of pulmonary vein isolation with a novel cryoballoon: Primary results of the FROZEN AF trial

Pulsed field ablation and cryoballoon ablation for pulmonary vein isolation: insights on efficacy, safety and cardiac function

Pulsed Field Versus Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation: Efficacy, Safety, and Long-Term Follow-Up in a 400-Patient Cohort

Efficacy of Ablation Index-Guided Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation.

Practical Techniques in Cryoballoon Ablation: How to Isolate Inferior Pulmonary Veins

Comparison of Arctic Front Advance Pro and POLARx cryoballoons for ablation therapy of atrial fibrillation: an intraprocedural analysis

Efficacy and safety of pulmonary vein isolation with pulsed field ablation vs. novel cryoballoon ablation system for atrial fibrillation

Novel Cryoballoon Technology for Atrial Fibrillation Ablation: Impact of Pulmonary Vein Variant Anatomy, Cooling Characteristics and 1-Year Outcome from the CHARISMA Registry

Balloon technologies for pulmonary vein isolation—12-month outcome and comparison of the novel radiofrequency balloon with the cryoballoon in patients with paroxysmal atrial fibrillation

Initial experience of a novel method for electrical isolation of the superior vena cava using cryoballoon in patients with atrial fibrillation

Randomised clinical trial of cryoballoon versus irrigated radio frequency catheter ablation for atrial fibrillation—the effect of double short versus standard exposure cryoablation duration during pulmonary vein isolation (CIRCA-DOSE): methods and rationale

VP122 Cryoballoon Versus Radiofrequency Ablation for Atrial Fibrillation

Balloon technologies for pulmonary vein isolation - long-term follow-up and comparison of the novel radiofrequency balloon with the cryoballoon in patients with paroxysmal atrial fibrillation

A Tailored Ablation Protocol

Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment

Performance of Two Tools for Pulmonary Vein Occlusion Assessment with a Novel Navigation System in Cryoballoon Ablation Procedure

Initial Real-World Experiences of Pulmonary Vein Isolation and Ablation of Non-Pulmonary Vein Sites Using a Novel Circular Array Pulsed Field Ablation Catheter

Cryoballoon Ablation of Atrial Fibrillation Without Demonstration of Pulmonary Vein Occlusion—The Simplify Cryo Study

Pentaspline Pulsed Field Ablation Catheter Versus Cryoballoon for Atrial Fibrillation Ablation: Results From a Prospective Comparative Study

Pulsed field versus cryoballoon ablation for atrial fibrillation: a real-world observational study on procedural outcomes and efficacy